Actinium Pharmaceuticals Unveils Preclinical Data Showing ATNM-400 Overcomes Breast Cancer Therapy Resistance
I'm PortAI, I can summarize articles.
Actinium Pharmaceuticals Inc. announced preclinical data for ATNM-400, an Actinium-225 antibody radioconjugate, showing significant anti-tumor activity in breast cancer models resistant to standard therapies. The data suggest ATNM-400 may overcome resistance to endocrine and HER2-targeted therapies and inhibit tumor growth in TNBC models. Results will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments